RecruitingPhase 2NCT07575308

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Adult and Adolescent Female Patients With Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

Sponsor

Alnylam Pharmaceuticals

Enrollment

24 participants

Start Date

Jul 30, 2026

Study Type

INTERVENTIONAL

Conditions

Von Willebrand Disease (vWD)Heavy Menstrual Bleeding (HMB)

Summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB

Eligibility

Sex: FEMALEMin Age: 16 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ALN-6400 for people with heavy menstrual bleeding (hmb) and von willebrand disease (vwd). The study is currently recruiting participants at 4 locations. People eligible for this study include women aged 16 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGALN-6400

ALN-6400 will be administered subcutaneously (SC).

Locations(11)

Clinical Trial Site

Orange, California, United States

Clinical Trial Site

San Diego, California, United States

Clinical Trial Site

San Francisco, California, United States

Clinical Trial Site

Miami, Florida, United States

Clinical Trial Site

Lexington, Kentucky, United States

Clinical Trial Site

Pittsburgh, Pennsylvania, United States

Clinical Trial Site

Nijmegen, Netherlands

Clinical Trial Site

Stockholm, Sweden

Clinical Trial Site

Bradford, United Kingdom

Clinical Trial Site

Oxford, United Kingdom

Clinical Trial Site

Truro, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07575308

Related Trials

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

NCT0711500414 locations

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

NCT0558299321 locations

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

NCT0675485225 locations

A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease

NCT076408939 locations

Algorithm-based Management to Reduce the Recurrence of GI Bleeding and Severe Epistaxis in Von Willebrand Disease

NCT0665125517 locations